Welcome to our dedicated page for Zura Bio news (Ticker: ZURA), a resource for investors and traders seeking the latest updates and insights on Zura Bio stock.
Zura Bio Limited (Nasdaq: ZURA) is a clinical-stage, multi-asset immunology company whose news flow centers on the development of novel antibodies for autoimmune and inflammatory diseases. Company announcements frequently highlight progress in its clinical pipeline, financial updates, and key corporate developments.
A major focus of Zura Bio’s news is tibulizumab (ZB-106), its lead investigational dual-pathway antibody targeting IL-17A and BAFF. Press releases describe the advancement of two Phase 2 trials: TibuSHIELD, a global randomized, double-blind, placebo-controlled study in adults with moderate to severe hidradenitis suppurativa, and TibuSURE, a global Phase 2 trial in adults with systemic sclerosis. Updates often cover trial initiation, enrollment status, study design details, and anticipated timelines for topline data readouts.
Investors and observers will also find quarterly and annual financial results reported by Zura Bio, including information on research and development spending, general and administrative expenses, net loss, and cash and cash equivalents. These releases typically include the company’s expectations about its cash runway and its ability to fund planned operations and clinical programs.
Additional news items include corporate and leadership changes, such as executive appointments, board transitions, and the establishment of advisory structures, as well as participation in healthcare and investor conferences where Zura Bio presents corporate overviews. The company also issues updates related to equity inducement grants and other compensation matters.
This news page aggregates these disclosures so readers can follow Zura Bio’s clinical milestones, financial condition, and organizational updates in one place. For those tracking ZURA, the feed offers an organized view of how the company’s immunology programs and corporate strategy are evolving over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Zura Bio Limited (Nasdaq: ZURA) has licensed tibulizumab, an anti-IL-17 and anti-BAFF dual antagonist, from Eli Lilly. The compound will be designated as ZB-106 and has already undergone two Phase 1b studies demonstrating an acceptable safety profile. Zura plans to initiate a Phase 2 study for ZB-106 in Systemic Sclerosis in 2024. Additionally, the company has announced a private placement financing to raise approximately $80 million, selling around 18.8 million Class A ordinary shares and pre-funded warrants. The financing is expected to enhance Zura’s cash reserves to approximately $120 million, sufficient to fund operations through 2026. The offering is led by multiple investment firms, and shares are priced at $4.25.